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Abstract
Second-generation antipsychotics (SGA) are multi-target agents widely used for the treatment of schizophrenia
and bipolar disorder that also hold potential for the treatment of impaired emotional control, thanks to their
diverse receptor proﬁles as well as their potential in modulating neuroadaptive changes in key brain regions.
The aim of this study was thus to establish the ability of lurasidone, a novel SGA characterized by a multi-
receptor signature, to modulate behavioural and molecular defects associated with a genetic model of impaired
emotional control, namely serotonin transporter knockout (SERT KO) rats. At behavioural level, we found that
chronic lurasidone treatment signiﬁcantly increased fear extinction in SERT KO rats, but not in wild-type control
animals. Moreover, at molecular level, lurasidone was able to normalize the reduced expression of the neuro-
trophin brain-derived neurotrophic factor in the prefrontal cortex of SERT KO rats, an eﬀect that occurred
through the regulation of speciﬁc neurotrophin transcripts (primarily exon VI). Furthermore, chronic lurasidone
treatment was also able to restore the reduced expression of diﬀerent GABAergic markers that is present in these
animals. Our results show that lurasidone can improve emotional control in SERT KO rats, with a primary
impact on the prefrontal cortex. The adaptive changes set in motion by repeated treatment with lurasidone may
in fact contribute to the amelioration of functional capacities, closely associated with neuronal plasticity, which
are deteriorated in patients with schizophrenia, bipolar disease and major depression.
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Introduction
Second-generation antipsychotics (SGAs) are multi-target
agents widely used for the treatment of schizophrenia
and bipolar disorders. However, their clinical action
and therapeutic utility has also expanded to disorders
characterized by impaired emotional control, such as
anxiety and depression, as monotherapy or as adjunctive
therapy to conventional antidepressants (DeBattista and
Hawkins, 2009 ; McElroy et al. 2010; Li et al. 2012). One
potential mechanism that explains the use of SGAs
in improving emotional control is their complex and
heterogeneous receptor proﬁle and, in particular, their
ability to modulate diﬀerent neurotransmitter receptors
beyond dopamine D2 (Wong et al. 2010). Furthermore,
it is widely accepted that, as a diﬀerence from classical
antipsychotics, SGAs may promote neuroadaptive and
neuroplastic changes, which may contribute to functional
recovery (Lieberman et al. 2008; Molteni et al. 2009b). For
example, a number of SGAs can increase the expression
of neurotrophic molecules under basal conditions (Riva et
al. 1999; Fumagalli et al. 2003; Maragnoli et al. 2004), and
may also normalize neuroplastic dysfunctions associated
with chronic stress exposure (Xu et al. 2006; Park et al.
2009).
Lurasidone is a novel SGA characterized by potent
binding aﬃnities for serotonin (5-HT)2A, 5-HT7, 5-HT1A,
dopamine D2 and noradrenaline a2C receptors (Ishibashi
et al. 2010). This multiple target aﬃnity has been as-
sociated with emotional control and antidepressant
properties, including blockade of 5-HT2A and 5-HT7, as
well as activation of 5-HT1A receptors (Ishibashi et al.
2010; Wong et al. 2010). Moreover, we have recently
shown that chronic, but not acute, administration of lur-
asidone can increase the expression of brain-derived
neurotrophic factor (BDNF) and is able to modulate its
responsiveness under stressful conditions (Fumagalli et al.
2012). This suggests that lurasidone has the potential to
boost adaptive mechanisms, which in turn may improve
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symptoms and functions that have deteriorated in
patients suﬀering from impaired emotional control,
including major depression (Pittenger and Duman, 2008;
Calabrese et al. 2009, 2011).
Since limited information is availablewith regard to the
ability of SGAs to improve emotional control in animal
models and to correct the molecular deﬁcits associated
with such condition, we decided to investigate the eﬀects
of chronic lurasidone exposure in serotonin transporter
(SERT) knockout rats, an animal model of mood dis-
turbance (Olivier et al. 2008; Schipper et al. 2011a, b ;
Nonkes et al. 2012). This model recapitulates defects
of the SERT due to the presence of a human functional
polymorphism within its promoter region, which mod-
ulates the susceptibility to diﬀerent neuropsychiatric
disorders (Caspi et al. 2003, 2010). Genetic deletion
of SERT in rodents in fact leads to an anxious and
depressive phenotype (Homberg et al. 2007; Olivier et al.
2008; Kalueﬀ et al. 2010; Schipper et al. 2011a, b) as well
as impaired fear extinction (Schipper et al. 2011a ; Nonkes
et al. 2012). Also, we have previously demonstrated
that SERT knockout (SERTx/x) rats exhibit alterations
in neuronal plasticity, as indicated by reduced expression
of the neurotrophin BDNF in the hippocampus and pre-
frontal cortex (PFC; Molteni et al. 2009a, 2010) and
that this defect is normalized by long-term adminis-
tration of the antidepressant duloxetine (Calabrese et al.
2010).
In the present study we used SERTx/x rats to speciﬁ-
cally address the potential of lurasidone to improve ex-
tinction in the fear-conditioning paradigm, a key measure
of emotional control that is impaired in post-traumatic
stress disorder (PTSD). Moreover, based on the role of the
PFC and BDNF in fear extinction (Milad and Quirk, 2002)
and considering the impaired expression of the neuro-
trophin in the PFC of SERTx/x rats (Molteni et al. 2010),
we also investigated whether chronic lurasidone admin-
istration could normalize the changes in the expression of
BDNF. Furthermore, we examined whether chronic treat-
ment with the antipsychotic drug could normalize dys-
regulation of GABAergic markers found in SERTx/x
rats (Guidotti et al. 2011), which are closely related to
BDNF function and may contribute to the aetiology and
manifestation of depressive disorders and impaired
emotional control (Sanacora et al. 1999; Luscher et al.
2011).
Method
Materials
General reagents and molecular biology reagents
were purchased from Bio-Rad Laboratories (Italy),
Euroﬁns MWG-Operon (Germany), Immuno Biological
Laboratories (Germany), Life Technologies (Italy),
M-Medical (Italy), Roche (Italy), Sigma-Aldrich (Italy)
and Thermo-Scientiﬁc (Belgium).
Animals and treatment
SERT knockout rats (Slc6a41Hubr) were generated in a
Wistar background by N-ethyl-N-nitrosurea-induced
mutagenesis (Smits et al. 2006) as described previously
(Homberg et al. 2007). Experimental animals were derived
from crossing heterozygous SERT knockout (SERT+/x)
rats that were outcrossed for at least 10 generations with
wild-type Wistar rats obtained from Harlan Laboratories
(The Netherlands). After weaning, aged 21 d, ear cuts
were taken for genotyping, which was performed by
Kbiosciences (UK). A total of 64 females were used for the
experiment and were maintained with food and water
available ad libitum. A 12-h light–dark cycle was main-
tained (lights on 08.00 hours). All experiments were
carried out in accordance with the current guidelines
laid down by the European Communities Council
Directive of 24 November 1986 (86/609/EEC), they were
approved by the Committee for Animal Experiments
of the Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands and all eﬀorts were made to
minimize animal suﬀering and to reduce the number of
animals used.
The experimental groups were as follows:
SERT+/++ vehicle ; SERTx/x+ vehicle ; SERT+/++
lurasidone (10 mg/kg.d for 21 d) ; SERTx/x+ lur-
asidone (10 mg/kg.d for 21 d).
While ‘antidepressant’ properties of lurasidone may
occur at low doses (Ishibashi et al. 2010; Hedlund et al.
2011), we used 10 mg/kg based on our previous data and
in order to establish the neuroplastic properties of the
drug at a full regimen, which may produce signiﬁcant
occupancy at several receptors, including dopamine D2
receptors (Ishibashi et al. 2010).
Rats were treated with vehicle or lurasidone for
3 wk. Lurasidone (provided by Dainippon Sumitomo
Pharma Co. Ltd, Japan) was prepared by suspending the
drug at a concentration of 10 mg/ml in a 1% hydroxy-
ethylcellulose solution and was administered per os (by
gavage) in the amount of 1 ml/kg according to the body
weight of the animals. The rats were killed 24 h after the
last administration, according to the timing we used in
our previous studies. This was followed by the dissection
of the PFC [deﬁned as Cg1, Cg3 and IL sub-regions cor-
responding to the plates 6–10, according to the atlas of
Paxinos and Watson (1996)], from 2-mm thick slices. The
brain specimens were frozen on dry ice and stored at
x80 xC for further analysis.
Fear conditioning
The fear conditioning test was carried out after 2-wk
lurasidone administration. Fear conditioning chambers
of Med Associates Inc. (USA) were used. The chambers
were equipped with metal shock grids, a speaker and a
camera, which was mounted in front of the chambers.
The chambers were housed in sound attenuated cubicles.
The rats were trained to acquire a Pavlovian association
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between an auditory stimulus [fear-conditioned stimulus
(CS) ; 30 s, 2 kHz, 85 dB] and a mild footshock (uncon-
ditioned stimulus ; 0.6 mA, 1 s), which terminated coin-
cidentally with the end of the fear-CS. On day 1 of the
test, animals were allowed to habituate 2 min to the
chamber, after which a total of ﬁve fear-CS–footshock
pairings were given with an interval of 1 min. After the
last pairing, rats were left in the chamber for another
2 min before they were returned to their home cage. Fear
conditioning and extinction were measured respectively
24 and 48 h after conditioning in the same context, to
measure both contextual and cue-induced fear responses.
After 2 min habituation (measurement of baseline/con-
textual freezing), a total of eight fear-CS presentations
were given with an interval of 2 min (¡50%). Notably,
during the ﬁrst eight sessions, fear conditioning without
extinction was measured. Extinction was manifested
during the second set of eight sessions, 48 h after fear
conditioning. Chambers were cleaned with 70% EtOH
after each session. Freezing (no visible movement except
respiration) was scored using the software package
Observer version 5.0 (Noldus Information Technology,
The Netherlands).
RNA preparation for real-time PCR and analysis of
mRNA levels
Total RNA was isolated by single-step guanidinium iso-
thiocyanate/phenol extraction using PureZol RNA iso-
lation reagent (Bio-Rad Laboratories, Italy) according to
the manufacturer’s instructions and quantiﬁed by spec-
trophotometric analysis. Following total RNA extraction,
the samples were processed for real-time polymerase
chain reaction (RT-PCR) to assess mRNA levels. A 5 mg
aliquot of each sample was treated with DNase to avoid
DNA contamination.
RNA was analysed by TaqMan qRT-PCR instrument
(CFX384 real time system, Bio-Rad Laboratories) using
the iScript one-step RT-PCR kit for probes (Bio-Rad
Laboratories). Samples were run in 384-well formats in
triplicate as multiplex reactions with a normalizing in-
ternal control (36B4). Probe and primer sequences of all
genes are summarized in Table 1 and were purchased
from Euroﬁns MWG-Operon (Germany) and from Life
Technologies. Thermal cycling was initiated with an in-
cubation at 50 xC for 10 min (RNA retrotranscription) and
then at 95 xC for 5 min (TaqMan polymerase activation).
After this initial step, 39 cycles of PCR were performed.
Each PCR cycle consisted of heating the samples at 95 xC
for 10 s to enable the melting process and then for 30 s at
60 xC for the annealing and extension reactions. A com-
parative cycle threshold method was used to calculate the
relative target gene expression.
Preparation of subcellular fractions for protein analysis
PFC tissue from the diﬀerent experimental groups was
homogenized in a glass–glass potter in ice-cold 0.32 MT
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sucrose buﬀer (pH 7.4) containing 1 mM HEPES, 0.1 mM
EGTA and 0.1 mM phenylmethylsulfonyl ﬂuoride, in the
presence of commercial cocktails of protease (Roche,
Italy) and phosphatase (Sigma-Aldrich) inhibitors. The
homogenate was clariﬁed (3000 g ; 10 min), obtaining a
pellet (P1) enriched in nuclear components, which was
resuspended in a buﬀer (20 mM HEPES, 0.1 mM dithio-
threitol, 0.1 mM EGTA) supplemented with protease and
phosphatase inhibitors. The supernatant (S1) was then
centrifuged (12 500 g ; 15 min) to obtain a clariﬁed fraction
of cytosolic proteins (S2). The pellet (P2), corresponding
to the crude membrane fraction, was resuspended in the
same buﬀer used for the nuclear fraction. Total protein
content was measured according to the Bradford protein
assay procedure (Bio-Rad, Italy), using bovine serum
albumin as calibration standard.
Analysis of glucocorticoid receptor translocation
Protein analysis was performed on nuclear (P1) and cy-
tosolic (S2) fractions. Equal amounts of protein (15 mg)
were run under reducing conditions on an SDS-poly-
acrylamide gel (8% SDS-PAGE) and then electro-
phoretically transferred onto polyvinylidene ﬂuoride
membranes. Unspeciﬁc binding sites were blocked for 1 h
in 5% bovine serum albumin in Tris-buﬀered saline con-
taining 0.2% sodium azide. Membranes were then in-
cubated with the polyclonal rabbit anti-glucocorticoid
receptor primary antibody (1 :500 ; Thermo-Scientiﬁc) in a
blocking solution at 4 xC overnight. Membranes were
washed with Tris-buﬀered saline containing 0.1%
Tween-20 and incubated for 1 h at room temperature
with a peroxidase-conjugated anti-rabbit IgG (1 :2000) in
Tris-buﬀered saline. Results were standardized using
b-actin as control protein, which was detected by evalu-
ating the band density at 43 kDa after blocking the
membranes with 10% non-fat dry milk and probing them
with a polyclonal antibody (1 :20 000, Sigma) followed by
a 1:20 000 dilution of peroxidase-conjugated anti-mouse
IgG (Sigma). Protein levels were calculated by measuring
the optical density of the autoradiographic bands using
Quantity One software (Bio-Rad). To ensure that the au-
toradiographic bands were in the linear range of inten-
sity, diﬀerent exposure times were used. b-Actin was
employed as an internal standard because its expression
is not regulated by the experimental paradigm used.
Statistical analyses and presentation of data
The eﬀect of drug treatment or genotype on the mRNA or
protein levels was analysed by two-way analysis of vari-
ance (ANOVA) followed by single contrast post hoc test,
in which drug (vehicle vs. lurasidone) and genotype
(wild-type vs. SERTx/x) were considered as indepen-
dent factors. Signiﬁcance for all tests was assumed for
p<0.05. Data are presented as means¡standard error
(S.E.M.) and are expressed as % change of wild-type/
vehicle-injected animals.
Results
Eﬀect of lurasidone on fear extinction in SERT
knockout rats
Pavlovian fear conditioning is a behavioural paradigm
with high construct validity. Whereas the fear-associated
cue triggers the activation of the PFC, contextual stimuli
speciﬁcally recruit the hippocampus. Both inhibit – either
directly or indirectly – the amygdala (Quirk and Beer,
2006). Since we previously found changes in BDNF ex-
pression in both the PFC and hippocampus (Molteni et al.
2010), we used the combined cue/contextual fear-con-
ditioning test to evaluate the ability of subchronic treat-
ment with lurasidone to counteract defects associated
with impaired function of SERT.
During fear conditioning, lurasidone-treated rats
showed increased freezing in response to the CS (which
ended with a footshock; F3,30=7.80, p<0.01). However,
there was no signiﬁcant genotype eﬀect or genotyper
treatment interaction (F>0.5<1.5 ; Fig. 1a). During
the fear-conditioning test, conducted 24 h after fear
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Fig. 1. Eﬀect of chronic lurasidone (Lur) treatment on serotonin
transporter knockout (SERTx/x) rats in the fear conditioning
test. The data show the acquisition curves during acquisition (a),
extinction (b) and extinction recall (c). Wild-type (SERT+/+) and
SERTx/x rats were tested after 14 d subchronic Lur treatment
lasting 21 d. The data represent the means¡S.E.M. % freezing
during conditioned stimulus (CS) presentation. ** p<0.01,
SERTx/x/Lur-treated group diﬀerent from SERTx/x/vehicle
(Veh)-treated group.
1322 A. Luoni et al.
conditioning, no signiﬁcant diﬀerences in freezing were
observed during baseline (reﬂecting contextual freezing),
as measured for 2 min before presentation of the ﬁrst au-
ditory stimulus (F>1<2 for all comparisons, data not
shown). When freezing during tone presentations was
analysed, a near signiﬁcant treatment eﬀect was noted
(F3,30=4.15, p=0.053; Fig. 1b). There was no genotype
eﬀect (F3,30=0.01, n.s.) and no treatmentrgenotype in-
teraction (F3,30=0.76, n.s.). Furthermore, none of the in-
teraction terms was signiﬁcant (Fj1.8, n.s.). Also, during
the ﬁrst extinction trial no signiﬁcant eﬀects were found
(treatment : F3,30=1.23, n.s. ; genotype : F3,30=0.030, n.s. ;
treatmentrgenotype interaction : F3,30=0.922, n.s.).
Forty-eight hours following the fear-conditioning test, the
animals were tested for fear extinction. Again, no sig-
niﬁcant diﬀerences were noted during baseline (F>1<2
for all comparisons, data not shown), prior to presen-
tation of the tone. There was an overall signiﬁcant
genotypertreatment interaction (F3,30=4.73, p<0.05),
indicating that lurasidone had a diﬀerential eﬀect in
SERTx/x and wild-type rats. We also found a signiﬁcant
treatment eﬀect (F3,30=8.50, p<0.005), but no overall
genotype eﬀect (F3,30=0.53, n.s. ; Fig. 1c). There was a
signiﬁcant trialrgenotype interaction (F3,30=5.20,
p<0.05), but the trialrtreatment interaction just missed
signiﬁcance (F3,30=5.20, p=0.056). There was no signiﬁ-
cant trialrtreatmentrgenotype interaction (F3,30=0.71,
n.s.). Subsequent testing revealed that lurasidone signiﬁ-
cantly increased fear extinction in SERTx/x rats
(F2,13=11.94, p<0.01), without a signiﬁcant trialrtreat-
ment interaction (F2,13=1.58, n.s.). In SERT+/+ rats, on
the other hand, lurasidone did not aﬀect fear extinction
(F2,17=0.33, n.s.). Finally, overall fear extinction was not
signiﬁcantly diﬀerent between vehicle treated SERT+/+
and SERTx/x rats (F2,14=2.72, n.s.), although repeated
measures ANOVA revealed that SERTx/x rats displayed
more freezing than wild-type rats during sessions 2, 3, 4,
5 and 6 (F2,17=5.87, p<0.05). Therefore, our data show
that SERTx/x, but not wild-type animals, proﬁt from
lurasidone treatment.
Restorative properties of lurasidone on alterations
of BDNF expression in the prefrontal cortex of
SERTx/x rats
It is known that the neurotrophin BDNF within the PFC
plays an important role in fear extinction (Peters et al.
2010) and we have also previously shown that SERTx/x
rats show reduced expression of the neurotrophin in this
brain region (Molteni et al. 2010). On these bases, we in-
vestigated whether BDNF expression in the PFC of
SERTx/x rats could be modulated by chronic lurasidone
treatment.
As shown in Fig. 2 and in agreement with our previous
data (Molteni et al. 2010), the expression of BDNF was
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Fig. 2. Chronic lurasidone (Lur) treatment modulates the levels of speciﬁc transcripts of brain-derived neurotrophic factor (BDNF) in
the prefrontal cortex of serotonin transporter knockout (SERTx/x) rats. The mRNA levels for total BDNF (a), long 3k-untranslated
region BDNF (b), BDNF exon I (c), IV (d) and VI (e) were measured in the prefrontal cortex of wild-type (SERT+/+) and SERTx/x rats
treated for 21 d with vehicle (Veh) or Lur and killed 24 h after the last injection. The data, expressed as a % change over SERT+/+/Veh
(set at 0%), are the means¡S.E.M. of six to 10 independent determinations. * p<0.05, ** p<0.01, *** p<0.001 vs. SERT+/+/Veh;
# p<0.05 vs. SERT+/+/Lur ; $$$ p<0.001 vs. SERTx/x/Lur (two-way analysis of variance with single contrast post hoc test).
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signiﬁcantly reduced in the PFC of SERTx/x rats, alter-
ation that was modulated by chronic lurasidone treat-
ment. In detail, we found that total BDNF mRNA levels
were signiﬁcantly reduced in SERTx/x rats indepen-
dently from the treatment (genotype eﬀect : F1,36=12.79,
p<0.01) and that lurasidone did not produce any
signiﬁcant alteration in the expression of the neuro-
trophin (treatment eﬀect : F1,36=0.02, p=0.879 ; Fig. 2a).
Conversely, with regard to the mRNA levels for long 3k
untranslated region (UTR) BDNF (Fig. 2b), which ident-
iﬁes a subset of transcripts that may be targeted to den-
drites (An et al. 2008), we found a signiﬁcant genotype
eﬀect (F1,33=6.46, p<0.05) and a signiﬁcant geno-
typertreatment interaction (F1,33=6.63, p<0.05). Indeed,
its mRNA levels were signiﬁcantly reduced in SERTx/x
rats (x47% vs. SERT+/+/vehicle, p<0.01) and, while
chronic administration of lurasidone did not alter the
expression in wild-type animals (x17% vs. SERT+/+/
vehicle, n.s.), it largely restored the levels of long 3k-
UTR BDNF mRNA expression in SERTx/x rats (x16%
vs. SERT+/+/vehicle, n.s.). These results suggest that
lurasidone selectively modulates the neurotrophin in the
PFC of SERTx/x rats.
In order to further characterize this modulatory ac-
tivity, we investigated the expression of three major
BDNF transcripts, which are controlled by separate pro-
moters and may be diﬀerentially targeted to dendrites
(Chiaruttini et al. 2008). In line with our previous work
(Molteni et al. 2010), the mRNA levels of exon I, IV and VI
were all signiﬁcantly down-regulated in SERTx/x rats,
although they underwent diﬀerential changes in re-
sponse to chronic lurasidone treatment (Fig. 2).
Speciﬁcally, the mRNA levels for BDNF exon I were re-
duced in these animals (x42% vs. SERT+/+/vehicle,
p<0.05), alteration that was normalized by chronic lur-
asidone administration (x15% vs. SERT+/+/vehicle,
n.s. ; Fig. 2c). Instead, when considering the expression
of exon IV, we found a signiﬁcant genotype eﬀect
(F1,34=17.37, p<0.001) and a signiﬁcant genotypertreat-
ment interaction (F1,34=7.41, p<0.05). The mRNA levels
of exon IV were markedly decreased in SERTx/x rats
(x60% vs. SERT+/+/vehicle, p<0.001; Fig. 2d), eﬀect
that was, to some extent, counteracted by lurasidone.
Finally, we found a signiﬁcant treatment (F1,31=16.84,
p<0.001) and genotypertreatment interaction (F1,31=
14.84, p<0.001) when investigating the expression of
BDNF exon VI (Fig. 2e), which is the main neurotrophin
transcript that undergoes dendritic targeting (Chiaruttini
et al. 2008; Baj et al. 2012). Exon VI mRNA levels were in
fact signiﬁcantly down-regulated in SERTx/x animals
(x39% vs. SERT+/+/vehicle, p<0.01) and chronic lur-
asidone administration completely normalized these
changes, actually leading to a signiﬁcant up-regulation of
its mRNA levels when compared to vehicle-injected/
SERT+/+ animals (p<0.001 vs. SERTx/x/vehicle). Of
note, chronic administration of lurasidone to wild-type
animals did not produce any signiﬁcant change of exon I,
IV and VI mRNA levels (see Fig. 2c–e), suggesting that the
novel antipsychotic exerts a restorative activity speciﬁ-
cally in SERTx/x rats.
To better understand how lurasidone may produce
diﬀerent transcriptional eﬀects in SERTx/x animals, we
decided to analyse the expression of transcription factors
known to regulate BDNF mRNA expression (Tao et al.
2002; Pruunsild et al. 2011). Exon IV represents the
best characterized transcript, which is regulated by dif-
ferent factors including neuronal PAS domain protein 4
(NPAS4), nuclear factor-kB, calcium-response factor
(CaRF) and aryl-hydrocarbon receptor nuclear translo-
cator 2 (Arnt2), some of which may also cooperate in
regulating exon I transcription (Lin et al. 2008; Pruunsild
et al. 2011). With regard to NPAS4 (Table 2), we found a
signiﬁcant genotype eﬀect (F1,28=4.29, p<0.05) and a
signiﬁcant genotypertreatment interaction (F1,28=5.25,
p<0.05). In line with our previous results (Guidotti et al.
2011), SERTx/x rats show a signiﬁcant reduction of
NPAS4 mRNA levels in the PFC (x38% vs. SERT+/+/
vehicle, p<0.05), although this eﬀect was minimally af-
fected by chronic lurasidone administration.
The ameliorative eﬀects produced by chronic
lurasidone treatment on the expression of BDNF exon I
(and to less extent on exon IV) in SERTx/x rats could be
sustained by changes of Arnt2 (Table 2), which co-
operates with NPAS4 in their transcriptional regulation
(Pruunsild et al. 2011). Indeed, when investigating
the mRNA levels for Arnt2, there was a signiﬁcant treat-
ment eﬀect (F1,45=7.57, p<0.01), its expression being
Table 2. Chronic lurasidone (Lur) treatment modulates the
expression of brain-derived neurotrophic factor-related
transcription factors in the prefrontal cortex of serotonin
transporter knockout (SERTx/x) rats
SERT+/+/
Veh
SERT+/+/
Lur
SERTx/x/
Veh
SERTx/x/
Lur
NPAS4 100¡11 74¡7 62¡7* 76¡5
ARNT2 100¡9 111¡5 111¡7 149¡11$/#
CaRF 100¡7 94¡8 73¡6* 112¡6$$
NF-kB 100¡9 87¡8 69¡8* 97¡6$
* p<0.05 vs. SERT+/+/vehicle [two-way analysis of variance
(ANOVA) with single contrast post hoc test (SCPHT)] ; $ p<0.05,
$$ p<0.01 vs. SERTx/x/vehicle (two-way ANOVA with
SCPHT) ; # p<0.05 vs. SERT+/+/lurasidone (two-way ANOVA
with SCPHT).
The mRNA levels for neuronal PAS domain protein 4 (NPAS4),
aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2),
calcium-response factor (CaRF) and nuclear factor (NF)-kB were
measured in the prefrontal cortex of wild-type (SERT+/+) and
SERTx/x rats treated for 21 d with vehicle (Veh) or Lur and
killed 24 h after the last injection. The data, expressed as a % of
SERT+/+/VEH (set at 100%), are the means¡S.E.M. of at least
ﬁve independent determinations.
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up-regulated by chronic lurasidone administration in
SERTx/x rats (+49% vs. SERT+/+/vehicle, p<0.05 vs.
SERTx/x/vehicle).
We next investigated the expression of CaRF, another
important regulator of BDNF transcription and in par-
ticular of exon IV (Tao et al. 2002; Zheng et al. 2011).
Although we did not ﬁnd signiﬁcant genotype or treat-
ment eﬀects, there was a statistically signiﬁcant geno-
typertreatment interaction (F1,31=5.35, p<0.05). In fact,
while lurasidone did not alter the expression of the tran-
scription factor expression when given to wild-type ani-
mals (x6%, vs. SERT+/+/vehicle, n.s.), CaRF mRNA
levels were signiﬁcantly reduced in SERTx/x rats
(x27% vs. SERT+/+/vehicle, p<0.05) and normalized
by chronic lurasidone treatment (+12% vs. SERT+/+/
vehicle, p<0.01 vs. SERTx/x/vehicle) (Table 2).
Hereafter, we also observed a signiﬁcant genotyper
treatment eﬀect (F1,34=6.48, p<0.05) in the regulation of
NFkB (Table 2). The expression of the transcription factor
was signiﬁcantly reduced in SERTx/x rats (x31% vs.
SERT+/+/vehicle, p<0.05), an eﬀect that was normal-
ized by chronic lurasidone treatment, which had no eﬀect
when administered to wild-type animals.
Given that the major modulatory activity of lurasidone
in SERTx/x rats was exerted on exon VI and considering
that exon VI promoter is the major target for corticoster-
one-mediated transcriptional regulation of BDNF
(Hansson et al. 2006), we investigated the possibility that
chronic lurasidone treatment could modulate the nuclear
translocation of glucocorticoid receptors (GR). We there-
fore analysed the ratio of GR protein levels between
nuclear (P1) and cytosolic (S2) compartment (P1/S2), as a
measure of its transcriptional activation and we found a
signiﬁcant treatment eﬀect (F1,19=6.01, p<0.05 ; Fig. 3). In
particular, GR translocation from the cytosol to the nu-
cleus is reduced in SERTx/x rats, although the eﬀect did
not reach statistical signiﬁcance (x19% vs. SERT+/+/
vehicle, n.s.). However, chronic treatment of SERTx/x
rats with lurasidone increased GR translocation to the
nucleus (+17% vs. SERT+/+/vehicle, p<0.05 vs.
SERTx/x/vehicle), an eﬀect that may contribute to the
increased transcription of BDNF exon VI (Fig. 2e).
Eﬀect of lurasidone treatment on the expression of the
DNA demethylating gene Gadd45b in SERTx/x rats
Several rodent studies suggest that epigenetic mech-
anisms may account for long-term changes in BDNF
expression (Martinowich et al. 2003). Indeed, we have
previously shown that reduced expression of BDNF exon
VI in SERTx/x rats is due to increased methylation of its
promoter (Molteni et al. 2010). This was sustained by the
reduced expression of the mRNA levels of growth arrest
and DNA-damage-inducible b (Gadd45b), a gene in-
volved in DNA demethylation of several promoters in-
cluding BDNF (Ma et al. 2009). On these bases, we
decided to investigate the mRNA levels of Gadd45b in
response to chronic lurasidone administration in wild-
type and SERTx/x rats. We found a signiﬁcant genotype
eﬀect (F1,46=4.95, p<0.05) and a signiﬁcant genotype
rtreatment interaction (F1,46=8.89, p<0.01). Indeed, as
shown in Fig. 4, Gadd45bmRNA levels were signiﬁcantly
reduced in SERTx/x rats (x30% vs. SERT+/+/vehicle,
p<0.001), whereas chronic lurasidone treatment, which
per se had no signiﬁcant eﬀect in wild-type animals (x9%
vs. SERT+/+/vehicle, n.s.), completely restored the
mRNA levels of the demethylating gene when given to
SERTx/x rats (x4% vs. SERT+/+/vehicle, n.s. and
p<0.05 vs. vehicle-treated/SERTx/x rats).
Modulation of GABA-related genes in SERTx/x rats
after chronic lurasidone administration
We have recently demonstrated that alterations of BDNF
expression in SERTx/x rats are paralleled by changes of
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Fig. 3. Chronic lurasidone (Lur) treatment modulates the
translocation of glucocorticoid receptor (GR) protein from the
cytosolic to the nuclear compartment in the prefrontal cortex of
serotonin transporter knockout (SERTx/x) rats. The ratio of the
GR protein levels between the P1 and S2 fractions were
measured in the prefrontal cortex of wild-type (SERT+/+) and
SERTx/x rats treated for 21 d with vehicle (Veh) or Lur and
killed 24 h after the last injection. The data, expressed as a %
change over SERT+/+/Veh (set at 0%), are the means¡S.E.M.
of at least four independent determinations. $ p<0.05 vs.
SERTx/x/Veh (two-way analysis of variance with single
contrast post hoc test).
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Fig. 4. Chronic lurasidone (Lur) treatment modulates the
expression of Gadd45b in the prefrontal cortex of serotonin
transporter knockout (SERTx/x) rats. The mRNA levels for
Gadd45b was measured in the prefrontal cortex of wild-type
(SERT+/+) and SERTx/x rats treated for 21 d with vehicle (Veh)
or Lur and killed 24 h after the last injection. The data, expressed
as a % change over SERT+/+/Veh (set at 0%), are the
means¡S.E.M. of at least nine independent determinations.
*** p<0.001 vs. SERT+/+/Veh; $ p<0.05 vs. SERTx/x/Veh
(two-way analysis of variance with single contrast post hoc test).
Lurasidone-induced neuronal plasticity 1325
the GABAergic system in the hippocampus and PFC
(Guidotti et al. 2011). Based on the close association be-
tween BDNF and GABA, we investigated the possibility
that chronic lurasidone treatment in SERTx/x rats could
be associated with signiﬁcant changes in the expression
of GABAergic markers within the PFC.
First, we investigated the expression of three key
elements of the GABAergic synapse, namely the vesicular
GABA transporter (VGAT), the GABA-producing
enzyme (GAD67) and the post-synaptic GABAA-receptor
c2 subunit (GABAA-c2) in the PFC of SERT
x/x rats. As
shown in Fig. 5a, we did not ﬁnd any signiﬁcant change
in the expression of VGAT mRNA levels, whereas the
expression of GAD67 was signiﬁcantly modulated by
SERT genotype (F1,45=8.77, p<0.01), although there was
no signiﬁcant genotypertreatment interaction (F1,45=
0.34, p=0.566). The mRNA levels of GAD67 were
signiﬁcantly reduced in SERTx/x rats (x19% vs.
SERT+/+/vehicle, p<0.05 ; Fig. 5b), an eﬀect that was not
observed when mutant animals were chronically treated
with lurasidone (x11% vs. SERT+/+/vehicle, n.s.). With
regard to the mRNA levels encoding for GABAA-c2
(Fig. 5c), a GABA receptor subunit primarily localized
at postsynaptic level, we found a signiﬁcant gene eﬀect
(F1,34=15.46, p<0.001), treatment eﬀect (F1,34=6.47,
p<0.05) and a signiﬁcant genertreatment interaction
(F1,34=12.94, p<0.01). Accordingly, GABAA-c2 mRNA
levels were markedly reduced in SERTx/x rats (x56%
vs. SERT+/+/vehicle, p<0.001) and this eﬀect was
normalized by chronic lurasidone treatment (x10%
vs. SERT+/+/vehicle, n.s. and p<0.001 vs. SERTx/x/
vehicle).
In order to establish whether the changes observed for
the GABAergic system were due to or related with the
modulation of subtypes of GABAergic neurons in the
PFC, we investigated the expression of a number of
putative markers, including parvalbumin (PV), calbindin
(CALB1) and somatostatin (SST). Speciﬁcally, with re-
gard to PV we found a signiﬁcant genotypertreatment
interaction (F1,44=7.26, p<0.05 ; Fig. 5d). PV mRNA levels
were in fact reduced in vehicle-treated SERTx/x rats
(x14% vs. SERT+/+/vehicle), although the eﬀect did not
reach statistical signiﬁcance, but its expression was in-
creased in SERTx/x rats that received chronic lurasidone
(+15% vs. SERT+/+/vehicle, p<0.05 vs. SERTx/x/ve-
hicle). A similar proﬁle was also found for SST, with a
signiﬁcant treatment eﬀect (F1,47=6.03, p<0.05 ; Fig. 5e).
The expression of SST was reduced in SERTx/x rats
(x21% vs. SERT+/+/vehicle, p<0.05), an eﬀect that was
completely normalized by chronic lurasidone adminis-
tration (+7% vs. SERT+/+/vehicle, n.s. ; p<0.05 vs.
SERTx/x/vehicle). A somewhat diﬀerent pattern of
changes was found for CALB1, whose expression was
modulated by lurasidone treatment (F1,33=14.09,
p<0.001) independently from the genotype [no gener
treatment interaction (F1,33=0.21, p=0.650)]. In fact, while
CALB1 mRNA levels were not altered in vehicle-treated
SERTx/x rats, chronic administration of lurasidone
increased its mRNA levels in wild-type (+33% vs.
SERT+/+/vehicle, p<0.05) as well as in SERTx/x rats
(+61% vs. SERT+/+/vehicle, p<0.05 vs. SERTx/x/
vehicle).
We also investigated neuropeptide Y and tachykinin 1,
two other markers of GABAergic neurons (Guilloux et al.
2011). However, no signiﬁcant changes were found with
regard to the expression of neuropeptide Y and tachyki-
nin 1 as a consequence of SERT deletion or chronic
lurasidone treatment (data not shown).
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Fig. 5. Chronic lurasidone (Lur) treatment modulates the expression of GABAergic systemmarkers in the prefrontal cortex of serotonin
transporter knockout (SERTx/x) rats. The mRNA levels for vesicular GABA transporter (a), GABA producing enzyme (b) and
GABAA-c2 (c), parvalbumin (d), somatostatin (e) and calbindin (f) were measured in the prefrontal cortex of wild-type (SERT
+/+) and
SERTx/x rats treated for 21 d with vehicle (Veh) or Lur and killed 24 h after the last injection. The data, expressed as a % change over
SERT+/+/Veh (set at 0%), are the means¡S.E.M. of at least six independent determinations. * p<0.05, *** p<0.001 vs. SERT+/+/Veh;
$ p<0.05, $$$ p<0.001 vs. SERTx/x/Veh (two-way analysis of variance with single contrast post hoc test).
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Discussion
In this study we demonstrate that the novel antipsychotic
lurasidone increases fear extinction in SERTx/x rats and
that this eﬀect may be sustained by BDNF modulation,
as well as by changes in the GABAergic system within
the PFC.
The failure to extinguish fear is a key feature of anxiety
and PTSD and it is a mechanism that can be modulated
by gene variants of SERT (Bryant et al. 2010). In fact, in
analogy with the human 5-HT transporter-linked poly-
morphic region ﬁndings (Pezawas et al. 2005; Heinz et al.
2007), SERTx/x rats show a failure to extinguish fear
after fear conditioning (Nonkes et al. 2012). In this study,
we observed a signiﬁcant genotypertreatment interac-
tion, indicating that lurasidone diﬀerentially increased
fear extinction (as measured 48 h after fear conditioning)
in SERTx/x rats. In turn, this suggests that chronic ad-
ministration of the novel antipsychotic may improve
some of the behavioural deﬁcits observed in these ani-
mals. This eﬀect of lurasidone is not likely to be due to its
eﬀects on the acquisition of fear conditioning, because
conditioned freezing during acquisition was increased in
lurasidone-treated rats, irrespective of genotype. In fact,
due to lurasidone’s eﬀect on acquisition, the eﬀect of
lurasidone on extinction (recall) eﬀectively may be larger
than presented. In contrast to our previous study that
measured cue-induced conditional fear (Nonkes et al.
2012), we found no signiﬁcant fear extinction deﬁcit in
SERTx/x rats. Most likely, this is because the animals
were exposed to the conditional tone in the training con-
text, such that cue- and context fear conditioning were
measured simultaneously. The baseline measurement
revealed no genotype diﬀerences in contextual freezing
and the absence of genotype diﬀerence in contextual
freezing may have weakened the impact of the cue-
induced freezing. Yet, there was a tendency towards
impaired fear extinction in SERTx/x rats under these
conditions, implying a stronger contribution of the PFC
rather than the hippocampus to the behavioural eﬀects of
lurasidone. Separate contextual and cue-induced fear
conditioning tests in future experiments would be helpful
to conﬁrm this implication.
Several studies have demonstrated that BDNF aﬀects
extinction of conditioned fear memories (Kaplan and
Moore, 2011). For example, extinction of conditioned fear
leads to an increase in BDNF mRNA expression in the
PFC and BDNF micro-infusion into the PFC induces
fear extinction (Bredy et al. 2007). Thus, the ability of
lurasidone to improve fear extinction in SERTx/x rats is
in line with the selective modulatory activity exerted
by lurasidone on BDNF expression within the PFC. Our
data in fact suggest that the restorative properties of
lurasidone on the BDNF changes found in the PFC of
SERTx/x rats may be primarily related to its ability to
regulate exon VI expression, although signiﬁcant changes
were also found for exon I and exon IV. Since BDNF exon
VI is the main contributor to BDNF mRNAs that undergo
dendritic targeting (Baj et al. 2011), these results are in
strong agreement with the observation that the main
modulatory eﬀect of lurasidone is exerted on the pool of
neurotrophin transcripts carrying a long 3kUTR. These
transcripts can undergo activity-dependent targeting to
the synaptic compartment (An et al. 2008) and may be
subjected to rapid and robust activation of translation
upon neuronal activation (Lau et al. 2010), representing a
mechanism for the ﬁne tuning of BDNF function and re-
sponsiveness.
The mechanisms through which lurasidone regulates
BDNF expression may involve diﬀerent transcription
factors that cooperate in the modulation of neurotrophin
transcripts (Pruunsild et al. 2011). Indeed, lurasidone up-
regulates the expression of Arnt2, which cooperates with
NPAS4 in promoting the transcription of BDNF exon I
and IV. In addition, chronic lurasidone normalizes the
reduced expression of NFkB and CaRF in SERTx/x rats,
which may also contribute to the transcriptional regu-
lation of BDNF (Pruunsild et al. 2011). However, it re-
mains to be established whether similar changes can be
found at protein level.
We also hypothesize that the modulation of GR con-
tributes to the changes in BDNF produced by lurasidone,
because chronic antipsychotic treatment increased the
nuclear translocation of GR in SERTx/x rats. We further
suggest that the restorative properties of lurasidone on
BDNF expression may be sustained by epigenetic me-
chanisms, as we have previously shown that reduced
expression of some BDNF transcripts is due to epigenetic
changes (Molteni et al. 2010). In particular, with regard to
exon VI, the transcript primarily modulated by lur-
asidone in SERTx/x rats, we found that its down-regu-
lation in these animals was due to increased methylation
of its promoter, an eﬀect that may be sustained by the
reduced expression of the DNA demethylating enzyme
Gadd45b (Ma et al. 2009; Molteni et al. 2010). We show
that chronic lurasidone treatment normalizes the reduced
expression of Gadd45b found in SERTx/x rats and, as a
consequence of this, we suggest that the signiﬁcant up-
regulation of BDNF exon VI expression in SERTx/x rats
that received chronic lurasidone could be sustained
by reduced methylation of its promoter. These results
highlight the possibility that Gadd45b can be pharmaco-
logically modulated and provide further support to the
notion that epigenetic-related mechanisms could indeed
represent an important aspect for the long-term activity
of psychotropic drugs, including lurasidone.
Chronic treatment with lurasidone not only restores
the reduced expression of BDNF in the PFC of SERTx/x
rats, but also ameliorates the impaired expression of
GABAergic markers in knockout animals, in particular
through a strong eﬀect on the mRNA levels for the post-
synaptic GABAA-c2 receptor subunit, as well as on pep-
tides that co-localize with GABA and that characterize
speciﬁc subtypes of GABAergic neurons. These results
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provide further support to the notion that neuronal de-
fects associated with the SERT genotype can be restored
by chronic treatment with lurasidone.
Although an alteration of GABAergic function cannot
be considered a hallmark for a speciﬁc psychiatric con-
dition, the reduced expression of several GABAergic
markers in the PFC of schizophrenic and depressed
subjects suggests that these changes may be shared by
both disorders (Mellios et al. 2009). There is also evidence
for a signiﬁcant correlation between GAD67 and SST
(Hashimoto et al. 2008), suggesting that GAD67 mRNA
expression in SERTx/x rats could be decreased in the
subset of GABA neurons that express SST. In the cerebral
cortex, SST co-localizes with GABA and has similar in-
hibitory functions on post-synaptic target neurons, which
may summate or synergize with GABA function.
There are some similarities between the eﬀects of
lurasidone and those produced by the serotonin–nor-
epinephrine reuptake inhibitor antidepressant duloxetine
in the same model (Calabrese et al. 2010; Guidotti et al.
2011). However, while the modulation of some BDNF
transcripts, such as exon VI, could represent a common
downstream target for duloxetine and lurasidone, the
mechanisms that may lead to such changes might diﬀer,
seen by the selective modulation of GADD45b by chronic
lurasidone, but not by duloxetine (F. Calabrese and M. A.
Riva, unpublished observations).
The neuroplastic properties of lurasidone occur de-
spite the signiﬁcant antagonism at dopamine D2 receptors
(estimated to be about 70–80% at the dose employed)
(Ishibashi et al. 2010), which is expected to have inhibi-
tory eﬀects on BDNF expression (Fumagalli et al. 2003;
Park et al. 2009). This suggests that other mechanisms,
such as 5-HT7 antagonism or 5-HT1A partial agonism,
alone or in combination (Ishibashi et al. 2010; Li et al.
2012), as well as the modulation of glutamate N-Methyl-
D-aspartate receptors (Yuen et al. 2012), may be respon-
sible for the modulatory activity of lurasidone seen on
BDNF and the GABAergic system. Future studies will try
to establish if lower doses of lurasidone, proven to be
eﬀective in animal models of depression (Ishibashi et al.
2010; Hedlund et al. 2011), will also possess neuroplastic
properties in the SERT model.
In summary, these results highlight the strong
modulatory activity of lurasidone on neurotrophic
mechanisms in the PFC, which have implications in
enhancing neuronal plasticity, but may also contribute
to the improvement of neurotransmitter-associated dys-
functions and ultimately to the recovery of the functional
changes associated with mood disorders.
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